TOTAL (R/R)

TOTAL (R/R)

A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance 


Study Treatments

Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction. 


Inclusion criteria


Exclusion criteria


Participating sites


Link